Navigation Links
Isis Reports Financial Results and Highlights for Third Quarter 2011
Date:11/7/2011

CARLSBAD, Calif., Nov. 7, 2011 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today announced its financial results for the quarter ended September 30, 2011.  The Company finished the third quarter of 2011 with a pro forma net operating loss (NOL) of $20.0 million and $44.9 million for the three and nine months ended September 30, 2011, respectively, compared to a pro forma NOL of $6.0 million and $23.1 million for the same periods in 2010.  The Company finished the third quarter of 2011 with nearly $365 million in cash.  

"Our most notable success this year has been the submission of the Kynamro™ marketing authorization application to the European Medicines Agency.  With this submission, we are one step closer to commercializing Kynamro for patients who are at great risk of dying from their cardiovascular disease.  Genzyme remains on track to submit the U.S. application for marketing approval in the fourth quarter and is actively preparing to launch Kynamro next year in the U.S. and Europe.  Kynamro represents the first major commercial opportunity for Isis, and we are looking forward to its potential launch next year," said B. Lynne Parshall, J.D., Chief Operating Officer, Chief Financial Officer and Secretary of Isis.  "Together with Genzyme, we are initiating our next Kynamro study, FOCUS FH, this year, which is intended to support an expansion of the market for Kynamro for severe forms of hypercholesterolemia.  We and Genzyme are committed to continuing investments in this novel medicine to make it available to as many patients as appropriate to treat their severe and fatal cardiovascular disease."

Upcoming Key Milestones

  • File for marketing approval for Kynamro™ (mipomersen) in the United States in the fourth quarter of 2011 for patients with homozygous Familial Hypercholesterolemia (FH
    '/>"/>

  • SOURCE Isis Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. Alexza Reports 2011 Third Quarter Financial Results and Provides Business Update
    2. Anadys Pharmaceuticals Reports Third Quarter 2011 Financial Results and Highlights
    3. Pharmacyclics Reports Fiscal 2012 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 53rd American Society of Hematology Annual Meeting
    4. Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results
    5. Vanda Pharmaceuticals Reports Third Quarter 2011 Results
    6. Cambrex Reports Third Quarter 2011 Results
    7. Dyadic International Reports 2011 Third Quarter Financial Results
    8. Rochester Medical Reports Fourth Quarter and Fiscal Year End Results
    9. Mettler-Toledo International Inc. Reports Third Quarter 2011 Results
    10. IRIDEX Reports 2011 Third Quarter and Nine-Month Results
    11. Cadence Pharmaceuticals Reports Third Quarter 2011 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:4/21/2015)... April 21, 2015  Legal-Bay LLC, The Lawsuit ... Boehringer Ingelheim Pharmaceuticals, is seeking FDA approval for ... According to PBR, Boehringer submitted a supplemental new ... that Pradaxa will be approved for the prophylaxis ... (PE) for patients who have undergone a primary ...
    (Date:4/20/2015)... is the daily "Profile America" feature from the U.S. ... Profile America — Tuesday, April 21st. One ... for general use this month in 1923, saving the ... is a hormone produced by the pancreas and is ... body. It was first isolated the year before by ...
    (Date:4/20/2015)... Gregory Taylor , Canada,s Chief Public Health ... a week in West Africa . The visit ... the ground as global efforts continue to reach zero Ebola cases. ... in Sierra Leone and Guinea ... work being done and hear from those on the front-lines about ...
    Breaking Medicine Technology:Pradaxa Maker Boehringer Ingelheim Pharmaceuticals Pursues Pradaxa FDA Approval to treat DVT and PE 2Pradaxa Maker Boehringer Ingelheim Pharmaceuticals Pursues Pradaxa FDA Approval to treat DVT and PE 3U.S. Census Bureau Daily Feature for April 21 2Canada's Efforts Making a Difference in the Fight Against Ebola 2Canada's Efforts Making a Difference in the Fight Against Ebola 3Canada's Efforts Making a Difference in the Fight Against Ebola 4Canada's Efforts Making a Difference in the Fight Against Ebola 5
    ... and CARLSBAD, Calif., Aug. 6 ,Genzyme Corp. (Nasdaq: ... ),today announced that they have begun a phase 3 ... a genetic,disorder that causes exceptionally high levels of LDL ... companies plan to initiate by the end of,this year, ...
    ... the most recent issue of,Optometry & Vision Development, two ... Fischer and his team which found,that children with vision ... that if the appropriate vision therapy is given,math skills ... several German television news,programs which reported on his research ...
    Cached Medicine Technology:Genzyme and Isis Begin Second Phase 3 Trial Of Mipomersen 2Genzyme and Isis Begin Second Phase 3 Trial Of Mipomersen 3Genzyme and Isis Begin Second Phase 3 Trial Of Mipomersen 4Genzyme and Isis Begin Second Phase 3 Trial Of Mipomersen 5Genzyme and Isis Begin Second Phase 3 Trial Of Mipomersen 6Genzyme and Isis Begin Second Phase 3 Trial Of Mipomersen 7Vision Problems Affect How Children Learn Math Skills 2
    (Date:4/21/2015)... On Saturday, May 2nd, 2015, board certified ophthalmologist ... from Georgia Eye Physicians and Surgeons will ... held in Piedmont Park by the Lupus Foundation of ... largest LFA-sponsored walk in the nation, hosting more than ... awareness for lupus, an unpredictable and potentially fatal autoimmune ...
    (Date:4/21/2015)... Antonio, TX (PRWEB) April 21, 2015 ... rights from a prestigious Illinois university for a ... care units (NICUs) more conducive to newborn infants’ ... the top three NICU problems we have identified ... neonatal care professionals,” said George Hutchinson, Invictus Medical’s ...
    (Date:4/21/2015)... 2015 “The warm summer season is fast ... want to look younger than her age? In the ... of defense. Signs of premature aging are deep ... too much time spent in the sun without adequate protection.” ... up. The dangers of UV rays can go deep ...
    (Date:4/20/2015)... (PRWEB) April 20, 2015 Heritage Woods ... host an Open House and Dine-and-Dash Spaghetti Dinner from ... The community, which is located in Centralia, Illinois, houses ... homes for low-income adults 55 and older. , Guests ... staff about supportive living options for seniors. After the ...
    (Date:4/20/2015)... (PRWEB) April 21, 2015 Using Quality ... CMOs Speed Production and Improve Compliance , **FDAnews Webinar**, ... EDT, http://www.fdanews.com/qualitybydesign , The life sciences industries ... them to do more with less. Mergers, acquisitions, ... CMOs to finds ways to speed up production while ...
    Breaking Medicine News(10 mins):Health News:9th Annual Walk to End Lupus Now 2Health News:9th Annual Walk to End Lupus Now 3Health News:Invictus Medical Secures Rights to Second Promising New NICU Technology 2Health News:Sun’s the Word this Mother’s Day Say’s SunGrubbies.com, a Leading Retailer of Sun Protection Products 2Health News:Heritage Woods of Centralia Senior Living Community to Host Open House and Spaghetti Dinner 2Health News:FDAnews Announces — Using Quality by Design to Improve Manufacturing: How Sponsors and CMOs Speed Production and Improve Compliance Webinar, May 7, 2015 2Health News:FDAnews Announces — Using Quality by Design to Improve Manufacturing: How Sponsors and CMOs Speed Production and Improve Compliance Webinar, May 7, 2015 3
    ... from various poultry farms across the state of Chattisgarh ... ,"Chhattisgasrh has not a single bird flu case ... at the High Security Animal Disease Lab at Bhopal," ... ,An official statement Thursday said the state government had ...
    ... Online counseling through Internet is gaining momentum slowly but surely ... practitioner// and discuss problems of any sort, as they do ... ,If the person being talked to is not visible, it ... or problems. ,"Psychotherapy is treatment for mental or ...
    ... Centers for Disease Control and Prevention highlights that very ... and contradicts the widely held public perception which blames ... ,The study for the first time challenges the ... HIV/AIDS, among the Blacks. The researchers of the present ...
    ... has caused the health officials to request the airlines ... Disease Control and Prevention have asked them to collect ... contact numbers and detailed flight information, to help track ... an additional expenditure on the airlines which is already ...
    ... various organizations are putting in their effort to combat the ... of the disease from the face of the earth. One ... India, and asked all the non-governmental organizations (NGOs) who are ... work as a unit. It asked them to co operate ...
    ... U.S. Army Medical Research Institute of Infectious Diseases and ... of Canada reported yesterday that the vaccine that is ... in monkeys after they were exposed to the deadly ... for the infection caused by Ebola virus. ...
    Cached Medicine News:Health News:Anonymity Helps In Overcoming Inhibitions During Online Counseling 2Health News:New Vaccine To Combat The Deadly Marburg Virus 2
    ... The Laserex Ultra Q is the fundamental ... cavity optimizes energy delivery and provides 2855% less ... to 2.54.0 mJs in contemporary systems. This ... dramatically reduces the risk of IOL pitting. ...
    ... Ultrasonix 500 is a high-end, mobile ultrasound ... architecture provides a tremendous amount of processing ... and resolution. Ultrasonix imaging systems provide ... including B, B/M, Pulsed Doppler, Color Doppler ...
    Protects the eye during or after surgery or trauma. Clear window dressing. Protects the eye allowing the patient to see....
    Protects the eye during or after surgery or trauma. 8mm diameter, lint free keeps cornea moist. Protects retina from operating microscope light rays....
    Medicine Products: